MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $8.50.

Several research analysts have weighed in on the stock. Cantor Fitzgerald dropped their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Citigroup began coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating on the stock. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Craig Hallum dropped their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd.

MiMedx Group Stock Down 0.3%

MiMedx Group stock opened at $3.57 on Wednesday. The firm has a market cap of $531.75 million, a PE ratio of 17.85 and a beta of 1.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The firm’s 50 day moving average price is $3.68 and its two-hundred day moving average price is $5.12. MiMedx Group has a twelve month low of $3.03 and a twelve month high of $7.99.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. On average, research analysts predict that MiMedx Group will post -0.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MDXG. Sunbelt Securities Inc. acquired a new position in shares of MiMedx Group during the 1st quarter worth $42,000. Kemnay Advisory Services Inc. bought a new stake in shares of MiMedx Group during the 4th quarter worth $48,000. Y Intercept Hong Kong Ltd acquired a new position in MiMedx Group in the 1st quarter valued at $65,000. Headlands Technologies LLC acquired a new position in MiMedx Group in the 2nd quarter valued at $72,000. Finally, Jain Global LLC bought a new position in MiMedx Group in the 4th quarter worth $73,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.